We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Taperloc Versus Taplerloc Microplasty

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00757107
First Posted: September 22, 2008
Last Update Posted: March 14, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Biomet U.K. Ltd.
Information provided by (Responsible Party):
Ingemar Ivarsson, University Hospital, Linkoeping
September 19, 2008
September 22, 2008
March 14, 2016
October 2011
October 2014   (Final data collection date for primary outcome measure)
Bone remodelling, i e change in bone mineral density around the stem, as measured with dual energy x-ray absorptiometry (DEXA) [ Time Frame: [ Time Frame: bone mineral density (BMD) measured postoperatively at 2 years ]
Pain, Function and Range of Motion [ Time Frame: 24months ]
Complete list of historical versions of study NCT00757107 on ClinicalTrials.gov Archive Site
Migration of stem components in six degrees of freedom and maximum total point motion measured with radiostereometric analysis [ Time Frame: 2 years ]
  • RSA [ Time Frame: 24 months ]
  • Survivorship [ Time Frame: 10 years ]
  • Complication [ Time Frame: Anytime ]
  • Clinical outcome measures with Harris Hip Score comparing patients receiving different stems. [ Time Frame: 3, 6, 12 and 24 months ]
  • Clinical outcome measures with Womac Score comparing patients receiving different stems. [ Time Frame: 3, 6, 12 and 24 months ]
Not Provided
 
Taperloc Versus Taplerloc Microplasty
Clinical Evaluation of Taperloc Total Hip System With Two Different Stem Lengths
This evaluation is conducted to evaluate the safety and performance of two different stem lengths of the Taperloc Total Hip System. Per implant bone loss and migration of the stem are compared between the two groups with Dual-energy X-ray absorptiometry (DEXA) and radiostereomektric analysis

Consecutive patients between 50 - 70 years diagnosed with primary osteoarthritis of the hip and eligible for total hip arthroplasty will be asked to participate in the study.

Periprosthetic bone loss, migration of the components and clinical scores will be recorded prospectively at 3,6,12 and 24 months.

Interventional
Not Provided
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Osteoarthritis
  • Device: Taperloc Microplasty
    primary total hip arthroplasty
  • Device: Taperloc standard
    primary total hip arthroplasty
  • Experimental: Taperloc Microplasty
    Patients with primary osteoarthritis with Taperloc microplasty non inferiority
    Intervention: Device: Taperloc Microplasty
  • Active Comparator: Taperloc Standard
    Patients with primary osteoarthritis Taperloc standard
    Intervention: Device: Taperloc standard
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
60
June 2015
October 2014   (Final data collection date for primary outcome measure)

Inclusion criteria:

  • Patients with primary osteoarthritis of the hip scheduled for THA.
  • Suitable anatomy for both stems
  • Willingness and ability to follow study-protocol

Exclusion Criteria

  • Malignancy or metastatic bone disease.
  • Any other disease severely affecting bone and mineral metabolism
  • Ongoing or previous treatment (within 5 years prior to inclusion) with steroids
  • Ongoing or previous treatment (within 5 years prior to inclusion) with antiresorptives.
  • Ongoing or previous treatment (within 5 years prior to inclusion) with immunosuppressive drugs.
  • Ongoing or previous treatment (within 5 years prior to inclusion) with anticonvulsive therapy.
  • Ongoing or previous treatment (within 5 years prior to inclusion) with hormonal therapy.
Sexes Eligible for Study: All
50 Years to 70 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Sweden
Norway
 
NCT00757107
GBMET.CR.ROWEU1
Yes
Not Provided
Plan to Share IPD: Yes
Ingemar Ivarsson, University Hospital, Linkoeping
Ingemar Ivarsson
Biomet U.K. Ltd.
Principal Investigator: Ingemar IVARSSON, PhD University hospital of Linkoping
University Hospital, Linkoeping
March 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP